Cochlear Hybrid Implant System
Cochlear Americas · Decision date Sep 28, 2026
What did the FDA decide?
FDA records P130016/S061 as a supplement to PMA P130016, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 28, 2026.
FDA approval order statement
a change to the joining process in the manufacturing of the NEUF Child Lock component in Cochlear Sound Processors
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Sep 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130016/S061
- Regulatory pathway
- PMA supplement
- Applicant
- Cochlear Americas
- Product code
- PGQ
- Decision code
- OK30
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cochlear implant with combined electrical stimulation and acoustic amplification.
- Applicant
- Cochlear Americas
- Product code
- PGQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P130016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P130016 · Original PMA
NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM
P130016/S061 received
Application receipt date recorded by FDA.
P130016/S061 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P130016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cochlear Americas | PMA approval | Mar 20, 2014 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cochlear Americas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10350 Park Meadows Dr., Lone Tree, CO, 80124
Sources and methodology
- Original FDA record: P130016/S061
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records